Piperidinyl-substituted lactams as gpr119 modulators

A compound having the general formula I

• or a pharmaceutically acceptable salt or solvate thereof, wherein:
• L is O or NRx;
• Rx is H or (1-3C)alkyl;
• X1 is N or CR1 and X2 is N or CR2, wherein only one of X1 and X2 may be N;
• R1, R2, R3 and R4 are independently selected from H, halogen, CF3, (1-6C)alkyl and (1-6C)alkoxy;
• R5 is (1-3C)alkylsulfonyl, (3-6C)cycloalkylsulfonyl, (cyclopropylmethyl)sulfonyl, phenylsulfonyl, CN, Br, CF3, triazolyl, (1-4C)alkoxycarbonyl, RxRyNHC(═O)—, oxadiazolyl optionally substituted with (1-3C)alkyl, and tetrazolyl optionally substituted with (1-3C)alkyl;
• or when X1 is CR1 and X2 is CR2, then R4 and R5 optionally together with the atoms to which they are attached form a 5-6 membered saturated heterocyclic ring having 1-2 ring heteroatoms independently selected from O and S and optionally substituted with an oxo group, wherein the S when present is optionally oxidized;
• Rx and Ry are independently (1-4C)alkyl optionally substituted with OH, or
• Rx and Ry together with the atom to which they are attached form a 5-6 membered saturated azacyclic ring optionally substituted with OH;
• R6 is H, OH or methyl;
• R6a is H or methyl;
• R7 is a group having the structure
• A1 is N or CRa;
• A2 is N or CRb;
• A3 is N or CRc;
• A4 is N or CRd,
• wherein at least one of A1, A2, A3 and A4 is N, and no more than two of A1, A2, A3 and A4 may be N;
• Ra, Rb, Rc and Rd are independently H, CF3, halogen, (1-4C)alkyl or CN;
• R8 is selected from hydrogen, halogen, CF3, CN, (1-10C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxy, (1-6C alkyl)sulfanyl, phenyl, pyridyl, pyrimidyl, pyrazolyl, and di(1-3C)alkylcarbamyl, wherein each of said phenyl, pyridyl, pyrimidyl, and pyrazolyl is optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyl, (1-4C)alkoxy and CF3;
• R9 and R9a are independently hydrogen or methyl;
• and
• n is 1, 2 or 3.